ZVSA - ZyVersa Therapeutics Operating income before deduction of amortization

Brandmark of ZyVersa Therapeutics Inc. (ZVSA)

ZyVersa Therapeutics (ZVSA) is developing a precision kidney therapy system utilizing its proprietary VAR 200 platform. The trend in pre-tax operating profit correlates with these developments, and reflects the current value of this metric. The business model relies on the outsourcing of production and trials. The environmental profile is limited to laboratory waste control, which minimizes capital expenditures.

zyversa.com (ZVSA) - Profit before payment of interest, taxes and amortization from 07/04/2022 to 11/13/2026

ZyVersa Therapeutics, Inc. - analytical breakdowns and key metrics (ZVSA)

- market price and analyst price targets:
Stock Price ZyVersa Therapeutics Inc.|ZVSA - Analyst Consensus Forecast
- market capitalization statistics:
Market Capitalization ZyVersa Therapeutics|ZVSA - Enterprise Value
- balance sheet equity data:
Equity per Share ZyVersa Therapeutics|ZVSA - Company Book Value|Capitalization to Book Value Ratio zyversa.com|ZVSA - Company Total Assets
- business debt structure and liquidity details:
Debt to Capital ZyVersa Therapeutics|ZVSA - Long-Term Debt to Equity Ratio|Current Liabilities to Capital ZyVersa Therapeutics Inc.|ZVSA - Company Total Debt|Debts to Book Capitalization Ratio ZyVersa Therapeutics|ZVSA - Company Long-Term Liabilities|Short-Term Debt ZyVersa Therapeutics|Quick Liquidity zyversa.com
- earnings and valuation multiples indicators:
ZVSA - Net Profit|Expected Net Profit ZyVersa Therapeutics|ZVSA - Price to Earnings Ratio|Future Price to Earnings Multiple ZyVersa Therapeutics Inc.|ZVSA - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio ZyVersa Therapeutics|ZVSA - Operating profit EBITDA|Net earnings per share (EPS TTM) ZyVersa Therapeutics|ZVSA - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months zyversa.com|ZVSA - Net earnings per share growth this year|Projected earnings per share increase next year ZyVersa Therapeutics
Fundamental company valuation:ZyVersa Therapeutics, ZVSA
Manufactured product of zyversa.com

For the biotech startup ZyVersa Therapeutics (ZVSA), which focuses on therapies for rare kidney pathologies, monthly EBITDA dynamics reflect the actual cash flow from operating activities before depreciation and taxes. Analyzing this indicator allows for the separation of one-time accounting adjustments from systemic liquidity growth, determining the funding stability for the development of innovative inflammasome inhibitors and the overall fundamental value of the business.

Competitor analysis for ZyVersa Therapeutics

Operating profit EBITDA Travere Corp TVTX|Ardelyx, Inc. - Operating profit EBITDA|Operating income before deduction of amortization prokidney.com PROK|AKBA: Operating profit EBITDA|Operating profit before amortization TVRD|Profit before payment of interest, taxes and amortization DiaMedica Pharma|Operating profit before amortization UNCY (Unicycive Therapeutics, Inc)|Operating profit EBITDA RMTI|CVKD - Profit before interest, taxes and amortization|Conduit Pharmaceuticals Inc. - Operating profit before deduction of amortization|Calliditas Therapeutics, Inc. (CALT) - Profit before interest, taxes and amortization|RNLX: Operating profit before deduction of amortization